AUTHORS
Melisande Beaumeunier, Martin Nicole2, Stephanie Harel, MD3, Virginie Siguret4, Nathalie Forgeard5, Camille Cohen6, Jonathan London7, Jerome Verrine8, Veronique Meignin9, Alexis R. Talbot, MD10, Bruno Royer, MD11, Floriane Theves12, Antoine Diep13, Damien Lorgeart14, Bertrand Arnulf Sr, MD, PhD15, Pierre-Edouard Debureaux, MD, PhD16
AFFILIATIONS
1 Saint Louis Hospital, Paris, France
2 Saint Louis Hospital, Paris, France
3 Saint Louis Hospital, Paris, France
4 Lariboisière, Paris, France
5 Saint Louis Hospital, Paris, France
6 Bichat, Paris, France
7 Croix Saint Simon, Paris, France
8 Saint Louis Hospital, Paris, France
9 Saint Louis Hospital, Paris, France
10 Saint Louis Hospital, Paris, France
11 Saint Louis Hospital, Paris, France
12 Saint Louis Hospital, Paris, France
13 Saint Louis Hospital, Paris, France
14 Lariboisière, Paris, France
15 Saint Louis Hospital, Paris, France
16 Saint Louis Hospital, Paris, France
ABSTRACT
BACKGROUND
Patients with systemic AL amyloidosis experience increased thrombotic and bleeding risks, a major comorbidity in this
setting. Thrombotic risk is mainly driven by atrial fibrillation/flutter, reported in 20–75% of amyloidosis patients in published
series, and possibly reinforced by nephrotic syndrome-related hypercoagulability. Bleeding risk, on the other hand, is
compounded by gastrointestinal amyloid infiltration, acquired factor X deficiency (< 50 IU/dL) — affecting up to 10% of patients — and
the concurrent use of anticoagulant therapy, increasingly direct oral anticoagulants (DOACs), in a population already prone
to spontaneous bleeding. Yet disease-specific guidance on anticoagulation strategy and risk stratification is still lacking,
especially in the current era of novel anti-plasma cell agents such as anti-CD38 monoclonal antibodies that are reshaping
disease control.
METHODS
COAGMYLOSE is a single-center retrospective study of histologically-confirmed AL amyloidosis patients (2010–2025).
Thrombotic and bleeding events were analyzed with Kaplan-Meier, competing-risk, and Cox models. CHA2DS2-VASc and
HAS-BLED discriminatory performance was evaluated in the subgroup with/without atrial fibrillation or flutter.
RESULTS
Among 114 AL amyloidosis patients, 81% had cardiac localisation, 32% with atrial fibrillation/flutter, 44% nephrotic syndrome, 19%
hepatic involvement, 32% gastrointestinal involvement, and 64% were on anticoagulant therapy. Anti-CD38 was introduced in first line in 2021.
Nine percent of patients experienced both a thrombotic and a bleeding event during follow-up.
Over a median 5-year follow-up, thrombotic events occurred in 20 patients (18%), more than half within the first year after
diagnosis; one third occurred despite ongoing anticoagulant therapy. Nephrotic syndrome was not significantly associated
with thrombotic risk (HR 0.82, 95%CI 0.31–2.16, p=0.69), including when restricted to venous events. Thrombosis had no
significant impact on overall survival, and CHA2DS2-VASc performed poorly at predicting thrombotic risk.
Bleeding was more frequent, affecting 56 patients (49%; 43% major/critical, mostly gastrointestinal), and HAS-BLED
retained discriminatory value for bleeding risk. Acquired factor X deficiency was observed in 36% of tested patients at the 70
IU/dL threshold (norm of the laboratory) and 11% at the 50 IU/dL threshold. Recovery was strikingly slow: at the 50 IU/dL threshold, median time to
normalization was 4.8 years, with 44% of patients never recovering; at the broader 70 IU/dL threshold, the majority (55%)
remained below normal by the end of follow-up. Factor X deficiency was independently associated with bleeding risk
(p=0.03), particularly among anticoagulated patients, and bleeding events were independently linked to reduced overall
survival (p=0.02, time-dependent analysis).
A landmark analysis at 2 years showed similar thrombotic incidence before and after the introduction of daratumumab in
first-line therapy (2021 cut-off: 11.9% vs 10.0%, respectively), despite a marked shift in first-line and antithrombotic
regimens over this period — daratumumab-based combinations rising from 4% to 56% of patients, and anticoagulation
shifting from vitamin K antagonists (12.5% to 2.4%) toward DOACs (8% to 29%).
CONCLUSIONS
Bleeding, more than thrombosis, appears as the main clinical burden in AL amyloidosis, driven largely by acquired factor X
deficiency and concurrent anticoagulation, including in patients on DOACs. Its persistent, often multi-year course argues for
systematic factor X screening before anticoagulant initiation and for individualized, closely monitored antithrombotic
strategies. Conventional thromboembolic risk scores seem poorly calibrated to this population — CHA2DS2-VASc notably
failed to predict thrombosis, while HAS-BLED remained informative for bleeding — supporting the need for amyloidosisspecific risk tools.
Despite substantial changes in first-line and antithrombotic treatment practices, thrombotic and bleeding
incidence remained stable across the study period, including after the introduction of anti-CD38 antibodies; this finding
should be interpreted cautiously given the shorter follow-up available in the most recent cohort.
DISCLOSURES
Pierre-Edouard Debureaux, MD, PhD: Meinarini - Honoraria; Sanofi - Honoraria; Pfizer - Honoraria; Beone - Research Funding